CLAIMS

1. A cannabis plant extract comprising a phytocannabinoid containing component and a non-phytocannabinoid containing component, for use in medicine, wherein the phytocannabinoid containing component comprises at least 50% (w/w) of the cannabis plant extract and the non-phytocannabinoid containing component comprises a monoterpene fraction and a sesquiterpene fraction, in which a principle monoterpene sub-fraction is selected from myrcenes or pinenes and a principle sesquiterpene sub-fraction is selected from caryophyllenes or humulenes.

2. The use of a cannabis plant extract comprising a phytocannabinoid containing component and a non-phytocannabinoid containing component, for use in the manufacture of a medicament for use in medicine, wherein the phytocannabinoid containing component comprises at least 50% (w/w) of the cannabis plant extract and the non-phytocannabinoid containing component comprises a monoterpene fraction and a sesquiterpene fraction and wherein a principle monoterpene sub-fraction is selected from myrcenes or pinenes and a principle sesquiterpene sub-fraction is selected from caryophyllenes or humulenes.

3. A cannabis plant extract or the use of a cannabis plant extract as claimed in claims 1 and 2, for use in the treatment of cancer.

4. A cannabis plant extract or the use of a cannabis plant extract as claimed in claims 1-3, wherein the principle monoterpene sub-fraction comprises myrcenes and the secondary monoterpene sub-fraction comprises pinenes.

5. A cannabis plant extract or the use of a cannabis plant extract as claimed in claims 1-4, wherein the principle monoterpenes sub-fraction comprises both myrcenes and pinenes.

6. A cannabis plant extract or the use of a cannabis plant extract as claimed in any of the preceding claims, wherein the principle sesquiterpene sub-fraction comprises caryophyllenes and secondary sesquiterpene sub-fraction comprises humulenes.

7. A cannabis plant extract or the use of a cannabis plant extract as claimed in any of the preceding claims, wherein the principle phytocannabinoid is selected from the group consisting of: tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabigerol propyl variant (CBGV), tetrahydrocannabivarinic acid (THCVA), tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), cannabigerol (CBG), tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabichromene (CBC).

8. A cannabis plant extract or the use of a cannabis plant extract as claimed in any of the preceding claims, wherein the non-phytocannabinoid containing component further comprises one or more compounds from the group consisting of: diterpenes; triterpenes; sterols; triglycerides; alkanes; squalenes; tocopherols; and carotenoids.

9. A cannabis plant extract or the use of a cannabis plant extract as claimed in any of the preceding claims, wherein the principle phytocannabinoid is CBG and the phytocannabinoid containing component comprises 61-75% (w/w) of the cannabis plant extract.

10. A cannabis plant extract or the use of a cannabis plant extract as claimed in claim 9, comprising greater than 88% (w/w) CBG of the total phytocannabinoid fraction.

11. A cannabis plant extract or the use of a cannabis plant extract as claimed in any of claims 1-8, wherein the principle phytocannabinoid is THC and the phytocannabinoid containing component comprises 77-94% (w/w) of the cannabis plant extract.

12. A cannabis plant extract or the use of a cannabis plant extract as claimed in claim 11, comprising 78-95% (w/w) THC of the total phytocannabinoid fraction.

13. A cannabis plant extract or the use of a cannabis plant extract as claimed in any of claims 1-8, wherein the principle phytocannabinoid is CBD and the phytocannabinoid containing component comprises 76-96% (w/w) of the cannabis plant extract.

14. A cannabis plant extract or the use of a cannabis plant extract as claimed in claim 13, comprising 72-88% (w/w) CBD of the total phytocannabinoid fraction.

15. A cannabis plant extract or the use of a cannabis plant extract as claimed in any of claims 1-8, wherein the principle phytocannabinoid is CBC and the phytocannabinoid containing component comprises 49-60% (w/w) of the cannabis plant extract.

16. A cannabis plant extract or the use of a cannabis plant extract as claimed in claim 15, comprising 71-87% (w/w) CBC of the total phytocannabinoid fraction.

17. A cannabis plant extract or the use of a cannabis plant extract as claimed in claim 16, which further comprises the secondary phytocannabinoids CBD and cannabicyclol (CBL).

18. A cannabis plant extract or the use of a cannabis plant extract as claimed in claim 17, wherein the CBD comprises 6.5-8% (w/w) of the total phytocannabinoid fraction and the CBL comprises 5.8-7.1 (w/w) of the total phytocannabinoid fraction.

19. A cannabis plant extract or the use of a cannabis plant extract as claimed in any of claims 1-8, wherein the principle phytocannabinoid is THCV and the phytocannabinoid containing component comprises 74-90% (w/w) of the cannabis plant extract.

20. A cannabis plant extract or the use of a cannabis plant extract as claimed in claim 19, comprising 71-87% (w/w) THCV of the total phytocannabinoid fraction.

21. A cannabis plant extract or the use of a cannabis plant extract as claimed in claim 20, which further comprises the secondary phytocannabinoid THC.

22. A cannabis plant extract or the use of a cannabis plant extract as claimed in claim 21, wherein the THC comprises 14.8-18% (w/w) of the total phytocannabinoid fraction.

23. A cannabis plant extract or the use of a cannabis plant extract as claimed in any of claims 1-8, wherein the principle phytocannabinoid is CBDV and the phytocannabinoid containing component comprises 64-78% (w/w) of the cannabis plant extract.

24. A cannabis plant extract or the use of a cannabis plant extract as claimed in claim 23, comprising 52-64% (w/w) CBDV of the total phytocannabinoid fraction.

25. A cannabis plant extract or the use of a cannabis plant extract as claimed in claim 24, which further comprises the secondary phytocannabinoids CBD and cannabichromene propyl variant (CBCV).

26. A cannabis plant extract or the use of a cannabis plant extract as claimed in claim 25, wherein the CBD comprises 22.4-27.4% (w/w) of the total phytocannabinoid fraction and the CBCV comprises 5.5-6.7 (w/w) of the total phytocannabinoid fraction.

27. A cannabis plant extract or the use of a cannabis plant extract as claimed in any of claims 1-8, wherein the principle phytocannabinoid is CBGV and the phytocannabinoid containing component comprises 54-66% (w/w) of the cannabis plant extract.

28. A cannabis plant extract or the use of a cannabis plant extract as claimed in claim 27, comprising 68-84% (w/w) CBGV of the total phytocannabinoid fraction.

29. A cannabis plant extract or the use of a cannabis plant extract as claimed in claim 28, which further comprises the secondary phytocannabinoid CBG.

30. A cannabis plant extract or the use of a cannabis plant extract as claimed in claim 29, wherein the CBG comprises 19-23% (w/w) of the total phytocannabinoid fraction.

31. A cannabis plant extract or the use of a cannabis plant extract as claimed in any of claims 1-8, wherein the principle phytocannabinoid is THCA and the phytocannabinoid containing component comprises 54-66% (w/w) of the cannabis plant extract.

32. A cannabis plant extract or the use of a cannabis plant extract as claimed in claim 31, comprising 71-86% (w/w) THCA of the total phytocannabinoid fraction.

33. A cannabis plant extract or the use of a cannabis plant extract as claimed in claim 32, which further comprises the secondary phytocannabinoid THC.

34. A cannabis plant extract or the use of a cannabis plant extract as claimed in claim 33, wherein the THC comprises 13.4-16.4% (w/w) of the total phytocannabinoid fraction.

35. A cannabis plant extract or the use of a cannabis plant extract as claimed in any of claims 1-8, wherein the principle phytocannabinoid is CBDA and the phytocannabinoid containing component comprises 71-86% (w/w) of the cannabis plant extract.

36. A cannabis plant extract or the use of a cannabis plant extract as claimed in claim 35, comprising 78-86% (w/w) CBDA of the total phytocannabinoid fraction.

37. A cannabis plant extract or the use of a cannabis plant extract as claimed in claim 36, which further comprises the secondary phytocannabinoid CBD.

38. A cannabis plant extract or the use of a cannabis plant extract as claimed in claim 37, wherein the CBD comprises 6.1-7.5% (w/w) of the total phytocannabinoid fraction.

39. A cannabis plant extract or the use of a cannabis plant extract as claimed in any of claims 1-8, wherein the principle phytocannabinoid is THCVA and the phytocannabinoid containing component comprises 62-75% (w/w) of the cannabis plant extract.

40. A cannabis plant extract or the use of a cannabis plant extract as claimed in claim 39, comprising 53-65% (w/w) THCVA of the total phytocannabinoid fraction.

41. A cannabis plant extract or the use of a cannabis plant extract as claimed in claim 40, which further comprises the secondary phytocannabinoid THCV.

42. A cannabis plant extract or the use of a cannabis plant extract as claimed in claim 41, wherein the THCV comprises 17.3-21.2% (w/w) of the total phytocannabinoid fraction.

43. A method of treating a patient comprising administering a therapeutically effective amount of a cannabis plant extract comprising a phytocannabinoid containing component and a non-phytocannabinoid containing component, wherein the phytocannabinoid containing component comprises at least 50% (w/w) of the cannabis plant extract and the non-phytocannabinoid containing component comprises a monoterpene fraction and a sesquiterpene fraction, in which a principle monoterpene sub-fraction is selected from myrcenes or pinenes and a principle sesquiterpene sub-fraction is selected from caryophyllenes or humulenes to the patient.

44. One or more phytocannabinoids, selected from the group consisting of: tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), tetrahydrocannabivarinic acid (THCVA), tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), cannabidiol (CBD), cannabigerol (CBG), and cannabichromene (CBC), for use in the treatment of hormone sensitive prostate cancer, wherein, where present, the THCVA is present as an isolated phytocannabinoid, the THCA, CBDA, CBD, CBG or CBC are present in the form of a botanical drug substance (BDS), and the THCV or CBDV are present in either an isolated form or in the form of a BDS.

45. The use of one or more phytocannabinoids, selected from the group consisting of: tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), tetrahydrocannabivarinic acid (THCVA), tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), cannabidiol (CBD), cannabigerol (CBG), and cannabichromene (CBC), for use in the manufacture of a medicament to treat of hormone sensitive prostate cancer, wherein, where present, the THCVA is present as an isolated phytocannabinoid, the THCA, CBDA, CBD, CBG or CBC are present in the form of a botanical drug substance (BDS), and the THCV or CBDV are present in either an isolated form or in the form of a BDS.

46. The one or more phytocannabinoids or the use of one or more phytocannabinoids as claimed in claim 44 or 45, wherein the one or more phytocannabinoids are propyl variant phytocannabinoids.

47. The one or more phytocannabinoids or the use of one or more phytocannabinoids as claimed in claim 44 or 45, wherein the one or more phytocannabinoids are in an acid form.

48. The one or more phytocannabinoids or the use of one or more phytocannabinoids as claimed in claims 44 to 46, wherein the one or more phytocannabinoids are in a neutral or decarboxylated form.

49. The one or more phytocannabinoids or the use of one or more phytocannabinoids as claimed in claim 44 or 45, wherein the phytocannabinoid is CBG and is in the form of a BDS.

50. The one or more phytocannabinoids or the use of one or more phytocannabinoids as claimed in claim 44 or 45, wherein the phytocannabinoid is THCVA in an isolated form.

51. A method of treating a patient with hormone sensitive prostate cancer comprising administering an effective amount of one or more phytocannabinoids, selected from the group consisting of: tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), tetrahydrocannabivarinic acid (THCVA), tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), cannabidiol (CBD), cannabigerol (CBG), and cannabichromene (CBC), wherein, where present, the THCVA is present as an isolated phytocannabinoid, the THCA, CBDA, CBD, CBG or CBC are present in the form of a botanical drug substance (BDS), and the THCV or CBDV are present in either an isolated form or in the form of a BDS to the patient.

52. One or more phytocannabinoids, selected from the group consisting of: tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), tetrahydrocannabivarinic acid (THCVA), tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), cannabidiol (CBD), cannabigerol (CBG), and cannabichromene (CBC), for use in the treatment of

hormone insensitive prostate cancer, wherein, where present, the THCVA is present as an isolated phytocannabinoid, the THCA, CBDA, CBD, CBG or CBC are present in the form of a botanical drug substance (BDS), and the THCV or CBDV are present in either an isolated form or in the form of a BDS.

53. The use of one or more phytocannabinoids, selected from the group consisting of: tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), tetrahydrocannabivarinic acid (THCVA), tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), cannabidiol (CBD), cannabigerol (CBG), and cannabichromene (CBC), for use in the manufacture of a medicament to treat of hormone insensitive prostate cancer, wherein, where present, the THCVA is present as an isolated phytocannabinoid, the THCA, CBDA, CBD, CBG or CBC are present in the form of a botanical drug substance (BDS), and the THCV or CBDV are present in either an isolated form or in the form of a BDS.

54. The one or more phytocannabinoids or the use of one or more phytocannabinoids as claimed in claim 52 or 53, wherein the one or more phytocannabinoids are propyl variant phytocannabinoids.

55. The one or more phytocannabinoids or the use of one or more phytocannabinoids as claimed in claim 52 or 53, wherein the one or more phytocannabinoids are in an acid form.

56. The one or more phytocannabinoids or the use of one or more phytocannabinoids as claimed in claims 52 to 54, wherein the one or more phytocannabinoids are in a neutral or decarboxylated form.

57. One or more phytocannabinoids, selected from the group consisting of: tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), tetrahydrocannabivarinic acid (THCVA), tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), cannabidiol (CBD), cannabigerol (CBG), and cannabichromene (CBC, for use in the treatment of prostate cancer, wherein, where present, the THCVA is present as an isolated phytocannabinoid, the THCA, CBDA, CBD, CBG or CBC are present in the form of a botanical drug substance (BDS), and the THCV or CBDV are present in either an isolated form

or in the form of a BDS, wherein the one or more phytocannabinoids are used in combination or as an adjunct therapy with a chemotherapeutic agent and / or an anti-androgen.

58. The use of one or more phytocannabinoids, selected from the group consisting of: tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), tetrahydrocannabivarinic acid (THCVA), tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), cannabidiol (CBD), cannabigerol (CBG), and cannabichromene (CBC, for use in the manufacture of a medicament to treat of prostate cancer, wherein, where present, the THCVA is present as an isolated phytocannabinoid, the THCA, CBDA, CBD, CBG or CBC are present in the form of a botanical drug substance (BDS), and the THCV or CBDV are present in either an isolated form or in the form of a BDS, wherein the one or more phytocannabinoids are used in combination or as an adjunct therapy with a chemotherapeutic agent and / or an anti-androgen.

59. The one or more phytocannabinoids or the use of one or more phytocannabinoids as claimed in claim 57 or 58, wherein the one or more phytocannabinoids are propyl variant phytocannabinoids.

60. The one or more phytocannabinoids or the use of one or more phytocannabinoids as claimed in claim 57 or 58, wherein the one or more phytocannabinoids are in an acid form.

61. The one or more phytocannabinoids or the use of one or more phytocannabinoids as claimed in claims 57 to 59, wherein the one or more phytocannabinoids are in a neutral or decarboxylated form.

62. The one or more phytocannabinoids or the use of one or more phytocannabinoids as claimed in claim 57 or 58, wherein the phytocannabinoid is CBG.

63. The one or more phytocannabinoids or the use of one or more phytocannabinoids as claimed in claim 57 or 58, wherein the phytocannabinoid is

CBD.

64. The one or more phytocannabinoids or the use of one or more phytocannabinoids as claimed in claim 62 or 63, wherein the phytocannabinoid is in the form of a BDS.

65. The one or more phytocannabinoids or the use of one or more phytocannabinoids as claimed in any of claims 57 to 64, wherein the chemotherapeutic agent is a mitotic inhibitor.

66. The one or more phytocannabinoids or the use of one or more phytocannabinoids as claimed in claim 65, wherein the mitotic inhibitor is from the taxane drug class.

67. The one or more phytocannabinoids or the use of one or more phytocannabinoids as claimed in claim 66, wherein the mitotic inhibitor from the taxane drug class is taken from the group: docetaxel; larotaxel; ortataxel; paclitaxel; and tesetaxel.

68. The one or more phytocannabinoids or the use of one or more phytocannabinoids as claimed in any of claims 57 to 67, for the purpose of slowing down the growth or reducing the volume of a prostate cancer tumour.

69. A method of treating a patient with prostate cancer comprising administering an effective amount of one or more phytocannabinoids, in combination or as an adjunct therapy with a chemotherapeutic agent and / or an anti-androgen, wherein the one or more phytocannabinoids is selected from the group consisting of: tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), tetrahydrocannabivarinic acid (THCVA), tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), cannabidiol (CBD), cannabigerol (CBG), and cannabichromene (CBC), wherein, where present, the THCVA is present as an isolated phytocannabinoid, the THCA, CBDA, CBD, CBG or CBC are present in the form of a botanical drug substance (BDS), and the THCV or CBDV are present in either an isolated form or in the form of a BDS, to the patient.

70. One or more phytocannabinoid acids for use in the treatment of breast cancer.

71. The use of one or more phytocannabinoid acids in the manufacture of a medicament for use in the treatment of breast cancer.

72. One or more phytocannabinoid acids or the use of one or more phytocannabinoid acids as claimed in any of claims 70 or 71, wherein the one or more phytocannabinoid acids are in the form of a botanical drug substance (BDS).

73. One or more phytocannabinoid acids or the use of one or more phytocannabinoid acids as claimed in claims 70 to 72, wherein the phytocannabinoid acid is taken from the group consisting of: tetrahydrocannabinolic acid (THCA), cannabigerolic acid (CBGA) and cannabidiolic acid (CBDA).

74. One or more phytocannabinoid acids or the use of one or more phytocannabinoid acids as claimed in claims 70 to 73, comprising in combination the phytocannabinoid THCA with CBDA and / or CBGA.

75. A method of treating breast cancer comprising administering a therapeutic amount of one or more phytocannabinoid acids to a patient.

76. An isolated cannabidiol (CBD), cannabigerol (CBG), cannabidivarin (CBDV), CBD botanical drug substance (BDS), CBG BDS and / or CBDV BDS for use in the treatment of a pre-cancerous symptom of colon cancer.

77. The use of isolated cannabidiol (CBD), cannabigerol (CBG), cannabidivarin (CBDV), CBD botanical drug substance (BDS), CBG BDS and / or CBDV BDS in the manufacture of a medicament for use to treat a pre-cancerous symptom of colon cancer.

78. Isolated CBD, CBG, CBDV, CBD BDS, CBG BDS and / or CBDV BDS or use of isolated CBD, CBG, CBDV, CBD BDS, CBG BDS and / or CBDV BDS as claimed in claim 76 or 77, wherein the isolated CBD, CBG, CBDV, CBD BDS,

CBG BDS and / or CBDV BDS are used in the treatment of aberrant crypts in the colon.

79. Isolated CBD, CBG, CBDV, CBD BDS, CBG BDS and / or CBDV BDS or use of isolated CBD, CBG, CBDV, CBD BDS, CBG BDS and / or CBDV BDS as claimed in claim 76 or 77, wherein the isolated CBD, CBG, CBDV, CBD BDS, CBG BDS and / or CBDV BDS are used in the treatment of colon polyps.

80. A method of treating a patient with a pre-cancerous symptom of colon cancer, comprising administering a therapeutically effective amount of an isolated cannabidiol (CBD), cannabigerol (CBG), cannabidivarin (CBDV), CBD botanical drug substance (BDS), CBG BDS and / or CBDV BDS to the patient.

81. A combination of phytocannabinoids together with temazolamide, for use in the treatment of a glioma.

82. The use of a combination of phytocannabinoids together with temazolamide, in the manufacture of a medicament to treat a glioma.

83. The combination or the use of the combination of phytocannabinoids as claimed in claim 81 or 82, wherein the combination of phytocannabinoids and the temazolamide are packaged for administration separately, simultaneously or sequentially.

84. The combination or the use of the combination as claimed in claims 81 to 83, wherein the phytocannabinoids are THC and CBD.

85. The combination or the use of the combination as claimed in claims 81 to 84, wherein the dose level of the phytocannabinoids is sub-effective for the treatment of the glioma if used alone.

86. The combination or the use of the combination as claimed in claims 81 to 85, wherein the dose level of the temazolamide is sub-effective for the treatment of

the glioma if used alone.

87. A method of treating a patient with a glioma comprising administering a therapeutically effective amount of a combination of phytocannabinoids together with temazolamide to the patient.

1. A combination of the phytocannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) together with temozolamide, for use in the treatment of a glioma, wherein the dose level of the phytocannabinoids and/or the temozolamide is sub-effective for the treatment of the glioma if used alone.

2. The use of a combination of the phytocannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) together with temozolamide, in the manufacture of a medicament to treat a glioma, wherein the dose level of the phytocannabinoids and/or the temozolamide is sub-effective for the treatment of the glioma if used alone.

3. The combination or the use of the combination of phytocannabinoids as claimed in claim 1 or 2, wherein the combination of phytocannabinoids and the temozolamide are packaged for administration separately, simultaneously or sequentially.